Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

Bullboard (OTCPK:ARLZQ)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Post by kuatoliveson May 24, 2017 3:56pm

Rats fleeing the sinking ship

https://www.conferencecalltranscripts.org/4/summary2/?id=3822812
181
Discussion
Comment by biggerron May 18, 2017 2:21pm

RE:RE:RE:RE:RE:RE:RE:Zacks gives ARZ a $6 target, yeah

up 5% in NY, shorts better cover, something's up
120
Discussion
Comment by biggerron May 18, 2017 12:38pm

RE:RE:RE:RE:RE:RE:Zacks gives ARZ a $6 target, yeah

it's now up 5 cents in the US, maybe Yosprala numbers are good, after all tens of millions taking aspirin
83
Discussion
Comment by biggerron May 18, 2017 10:37am

RE:RE:RE:RE:RE:Zacks gives ARZ a $6 target, yeah

in the US ARLZ is unchanged while they dumping it in Canada, WTH
89
Discussion
Comment by biggerron May 17, 2017 2:39pm

RE:RE:RE:RE:Zacks gives ARZ a $6 target, yeah

wow, to be up on a day like today shows that ARZ has hit the bottom and it's only up from here
99
Discussion
Comment by biggerron May 16, 2017 1:29pm

RE:RE:RE:Zacks gives ARZ a $6 target, yeah

I knew that ARZ would fall after the Zack target because shorts like to make a point that they are not scared, ha
98
Discussion
Comment by GoldenDilemmaon May 16, 2017 12:35pm

RE:RE:Zacks gives ARZ a $6 target, yeah

Zack's has been pumping ARLZ since summer of 2015. Stop listening to Zack's. 
81
Discussion
Comment by kuatoliveson May 16, 2017 12:16pm

RE:Zacks gives ARZ a $6 target, yeah

And if zontivity doesn't sell, the debt will overwhelm the company and that will be it.
85
Discussion
Post by biggerron May 15, 2017 5:47pm

Zacks gives ARZ a $6 target, yeah

https://finance.yahoo.com/news/arlz-zontivity-officially-launched-june-170000527.html
217
Discussion
Comment by kuatoliveson May 11, 2017 5:38pm

RE:RE:RE:RE:RE:The Cost of Not Taking Your Medicine

Why do you actually believe them? They haven't been right about anything, once.
92
Discussion
Comment by biggerron May 11, 2017 10:02am

RE:RE:RE:RE:RE:The Cost of Not Taking Your Medicine

the CXR people must be buying ARZ after the former crashed yesterday, ARZ is the only roll up pharma up today
101
Discussion
Comment by biggerron May 10, 2017 6:14pm

RE:RE:RE:RE:The Cost of Not Taking Your Medicine

no, really - ARZ has dropped by half from $4 in March on bad EBITDA guidance and then on bad Yos news. Now the EBITDA guidance has improved significantly and Yos is also looking up but the SP is ...more  
151
Discussion
Comment by GoldenDilemmaon May 10, 2017 11:38am

RE:RE:RE:The Cost of Not Taking Your Medicine

Really, the nerve of you bulls. About as deluded and arrogant as it can get. Again, nearly $13/share in August of 2015 down to nearly $1 in ths past week. A forthcoming launch of Zontivity which ...more  
149
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities